| scholarly article | Q13442814 |
| P50 | author | Gerard J. P. van Westen | Q30086276 |
| Adriaan P IJzerman | Q40222626 | ||
| Lindsey Burggraaff | Q61456437 | ||
| Clément Chalet | Q88675501 | ||
| Johan Nicolaï | Q88824030 | ||
| Paul Oranje | Q92435303 | ||
| Tom de Bruyn | Q92435307 | ||
| P2093 | author name string | Niels de Roo | |
| Guus Duchateau | |||
| Pieter Annaert | |||
| Marian Geldof | |||
| Robin Gouka | |||
| Fenja Clauwaert | |||
| Mario Vermeer | |||
| Pieter van der Pijl | |||
| Toon Vanpaeschen | |||
| P2860 | cites work | Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats | Q24563606 |
| Piceid, the major resveratrol derivative in grape juices | Q28137986 | ||
| ChEMBL: a large-scale bioactivity database for drug discovery | Q28315179 | ||
| The ChEMBL database in 2017 | Q28584450 | ||
| SGLT1-mediated Transport in Caco-2 Cells Is Highly Dependent on Cell Bank Origin | Q33459228 | ||
| The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose | Q34121476 | ||
| Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors | Q34222752 | ||
| Development of a novel non-radioactive cell-based method for the screening of SGLT1 and SGLT2 inhibitors using 1-NBDG. | Q34343670 | ||
| Acute anti-hyperglycaemic effects of an unripe apple preparation containing phlorizin in healthy volunteers: a preliminary study. | Q34424092 | ||
| Inhibition of the intestinal sodium-coupled glucose transporter 1 (SGLT1) by extracts and polyphenols from apple reduces postprandial blood glucose levels in mice and humans | Q35215364 | ||
| Traditional uses, phytochemistry and pharmacological properties of the genus Peucedanum: a review | Q35240578 | ||
| Development and application of a fluorescent glucose uptake assay for the high-throughput screening of non-glycoside SGLT2 inhibitors | Q35589371 | ||
| Contribution of hyperglycemia on diabetic complications in obese type 2 diabetic SDT fatty rats: effects of SGLT inhibitor phlorizin | Q35594390 | ||
| Structural selectivity of human SGLT inhibitors | Q35895528 | ||
| Phlorizin: a review | Q35995949 | ||
| Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9) | Q36529674 | ||
| Hypoglycemia in falciparum malaria: is fasting an unrecognized and insufficiently emphasized risk factor? | Q36535373 | ||
| Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease | Q36845771 | ||
| Calcium channel blocker use is associated with lower fasting serum glucose among adults with diabetes from the REGARDS study | Q36952295 | ||
| Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy | Q37461695 | ||
| New developments in the management of malaria in adults | Q37573181 | ||
| Biology of human sodium glucose transporters | Q37870037 | ||
| The science of hypoglycemia in patients with diabetes | Q38090714 | ||
| SGLT inhibitors in management of diabetes | Q38195440 | ||
| Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects | Q38447305 | ||
| Active learning for computational chemogenomics | Q38750215 | ||
| Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus. | Q38783130 | ||
| Intestinal SGLT1 in metabolic health and disease | Q38787917 | ||
| LX2761, a Sodium/Glucose Cotransporter 1 Inhibitor Restricted to the Intestine, Improves Glycemic Control in Mice | Q38820095 | ||
| Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective | Q38830703 | ||
| Glucose metabolism in quinine-treated patients with uncomplicated falciparum malaria | Q38963895 | ||
| Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. | Q39017610 | ||
| Pteryxin: a coumarin in Peucedanum japonicum Thunb leaves exerts antiobesity activity through modulation of adipogenic gene network | Q39311797 | ||
| Partially purified Peucedanum japonicum Thunb extracts exert anti-obesity effects in vitro. | Q39311802 | ||
| Verapamil Use Is Associated With Reduction of Newly Diagnosed Diabetes Mellitus | Q40268100 | ||
| Cellular uptake and efflux of trans-piceid and its aglycone trans-resveratrol on the apical membrane of human intestinal Caco-2 cells. | Q40462942 | ||
| Baculovirus-mediated expression of the Na+/glucose cotransporter in Sf9 cells | Q41639422 | ||
| Anti-adipogenic and anti-diabetic effects of cis-3',4'-diisovalerylkhellactone isolated from Peucedanum japonicum Thunb leaves in vitro | Q42807675 | ||
| ε-Viniferin, a resveratrol dimer, prevents diet-induced obesity in mice | Q42817816 | ||
| Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. | Q42944430 | ||
| Pyranocoumarins: a new class of anti-hyperglycemic and anti-dyslipidemic agents. | Q43265449 | ||
| trans-Resveratrol and ε-viniferin decrease glucose absorption in porcine jejunum and ileum in vitro | Q44466667 | ||
| Study design and rationale of a dose-ranging trial of LX4211, a dual inhibitor of SGLT1 and SGLT2, in type 2 diabetes inadequately controlled on metformin monotherapy. | Q44757675 | ||
| Global aetiology and epidemiology of type 2 diabetes mellitus and its complications | Q45305959 | ||
| LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose | Q46112762 | ||
| Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes | Q46764321 | ||
| DrugBank 5.0: a major update to the DrugBank database for 2018. | Q47128239 | ||
| Peucedanum japonicum Thunb inhibits high-fat diet induced obesity in mice | Q47341213 | ||
| Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis With Trial Sequential Analysis | Q47652080 | ||
| Discovery of LX2761, a Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitor Restricted to the Intestinal Lumen, for the Treatment of Diabetes | Q48100728 | ||
| SGLT1 and SGLT1 Inhibitors: A Role to Be Assessed in the Current Clinical Practice. | Q48234166 | ||
| Polydatin improves glucose and lipid metabolism in experimental diabetes through activating the Akt signaling pathway. | Q51314295 | ||
| Hypoglycaemic coma occurring during treatment with chlorpromazine and orphenadrine | Q52128601 | ||
| Effect of Peucedanum japonicum Thunb extract on high-fat diet-induced obesity and gene expression in mice. | Q54327290 | ||
| Identification of novel small molecule inhibitors for solute carrier SGLT1 using proteochemometric modeling | Q64139542 | ||
| Pharmacokinetics of quinine in young and elderly subjects | Q67873763 | ||
| Effect of bepridil on metabolic control and insulin secretion in diabetics | Q68152871 | ||
| Improvement of glucose tolerance by verapamil in patients with non-insulin-dependent diabetes mellitus | Q70186434 | ||
| Calcium channel blockers modify jejunal uptake of D-galactose in rabbits | Q71506803 | ||
| Changes in the phytoalexin content of various Vitis spp. in response to ultraviolet C elicitation | Q73160073 | ||
| A high cholesterol diet blocks the effect of calcium channel blockers on the uptake of sugars in rabbit intestine | Q73217927 | ||
| Polydatin supplementation ameliorates diet-induced development of insulin resistance and hepatic steatosis in rats | Q85837484 | ||
| Synthesis and biological evaluation of benzocyclobutane-C-glycosides as potent and orally active SGLT1/SGLT2 dual inhibitors | Q88012603 | ||
| Discovering Highly Potent Molecules from an Initial Set of Inactives Using Iterative Screening | Q91061830 | ||
| SGLT1 inhibition: Pros and cons | Q91627025 | ||
| P433 | issue | 4 | |
| P304 | page(s) | e00504 | |
| P577 | publication date | 2019-07-30 | |
| P1433 | published in | Pharmacology Research & Perspectives | Q27725410 |
| P1476 | title | Novel natural and synthetic inhibitors of solute carriers SGLT1 and SGLT2 | |
| P478 | volume | 7 |
Search more.